See What HealthDay Can Do For You
Contact Us

Tamoxifen Cost Questioned for Low-Risk Women

Drug's impact small for women at 5-year risk of 1.67 percent

TUESDAY, July 25 (HealthDay News) -- Tamoxifen is not likely to significantly impact the mortality of women at a five-year breast cancer risk of 1.67 percent, the U.S. Food and Drug Administration-approved threshold for chemoprevention, according to a report published online July 24 in Cancer. In addition, tamoxifen would be a more cost-effective therapy in the United States if prices were comparable to those in Canada.

Joy Melnikow, M.D., of the University of California-Davis in Sacramento, Calif., and colleagues forecast the effect of tamoxifen on cancer death rates and its cost-effectiveness for a hypothetical group of 50-year-old women.

The researchers forecast similar mortality risk for women with a five-year breast cancer risk of 1.67 percent, whether they took tamoxifen or not, and calculated that the cost of tamoxifen use was $1,335,690 per life-year saved.

Canadian prices dropped costs to $123,780 per life-year saved. At that price, the drug was more effective for women whose five-year breast cancer risk exceeded 4 percent.

Tamoxifen increased the risk of death due to side effects for women with a uterus until the five-year breast cancer risk was higher than 2.1 percent.

"Tamoxifen may increase mortality in women at the lower end of the 'high-risk' range for breast cancer," the authors write. "If prices in the U.S. approximated Canadian prices, then tamoxifen use for breast cancer risk reduction in women with a five-year risk greater than 3 percent could be a reasonable strategy to reduce the incidence of breast cancer."

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.